ARYA Sciences Acquisition Corp. III  (NASDAQ:ARYA) announced in an 8-K filing that its shareholders approved its combination with Nautilus Biotechnology at a special meeting earlier today.

The SPAC did not disclose redemption figures, but noted that 75.68% of shares participated in the vote, and the combination was approved nearly unanimously.

The transaction is now expected to close on June 9 with with the combined entity’s shares commencing trading on the Nasdaq under the symbols “NAUT” respectively on June 10.

The parties initially announced their $905 million deal on February 8. Nautilus is working to create a machine-learning technology platform for testing and mapping proteins and serve as an accelerant in biopharmaceutical research.

Although all measures on ARYA’s ballot passed by wide margins, some advisory governing document proposals received pushback. For a full list of proposals and vote tallies, click HERE.

ADVISORS

• Morgan Stanley is acting as lead financial advisor to Nautilus Biotechnology, with Cowen also acting as financial advisor to Nautilus Biotechnology.
• Wilson Sonsini Goodrich & Rosati, P.C., is acting as legal counsel to Nautilus Biotechnology.
• Jefferies LLC and Goldman Sachs & Co. LLC are acting as financial advisors to Arya III as well as private placement agents.
• Kirkland & Ellis LLP is acting as legal counsel to Arya III.